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Abstract
Background: Tuberous sclerosis complex (TSC) is an autosomal dominant tumor suppressor syndrome,
characterized by hamartomatous growths in the brain, skin, kidneys, lungs, and heart, which lead to significant
morbidity. TSC is caused by mutations in the TSC1 or TSC2 genes, whose products, hamartin and tuberin, form
a tumor suppressor complex that regulates the PI3K/Akt/mTOR pathway. Early clinical trials show that TSC-
related kidney tumors (angiomyolipomas) regress when treated with the mammalian target of rapamycin (mTOR)
inhibitor, rapamycin (also known as sirolimus). Although side effects are tolerable, responses are incomplete, and
tumor regrowth is common when rapamycin is stopped. Strategies for future clinical trials may include the
investigation of longer treatment duration and combination therapy of other effective drug classes.
Results: Here, we examine the efficacy of a prolonged maintenance dose of rapamycin in Tsc2+/- mice with TSC-
related kidney tumors. Cohorts were treated with rapamycin alone or in combination with interferon-gamma
(IFN-g). The schedule of rapamycin included one month of daily doses before and after five months of weekly
doses. We observed a 94.5% reduction in kidney tumor burden in Tsc2+/- mice treated (part one) daily with
rapamycin (8 mg/kg) at 6 months ≤ age < 7 months, (part 2) weekly with rapamycin (16 mg/kg) at 7 months ≤ age
< 12 months, and (part 3) daily with rapamycin (8 mg/kg) at 12 months ≤ age < 13 months; but we did not observe
any improvement with combination IFN-g plus rapamycin in this study. We also used a Tsc2-/- subcutaneous tumor
model to evaluate other classes of drugs including sorafenib, atorvastatin, and doxycycline. These drugs were
tested as single agents and in combination with rapamycin. Our results demonstrate that the combination of
rapamycin and sorafenib increased survival and may decrease tumor volume as compared to rapamycin treatment
alone while sorafenib as a single agent was no different than control. Atorvastatin and doxycycline, either as single
agents or in combination with rapamycin, did not improve outcomes as compared with controls.
Conclusion: Our results indicate that prolonged treatment with low doses of mTOR inhibitors may result in
more complete and durable TSC-related tumor responses, and it would be reasonable to evaluate this strategy
in a clinical trial. Targeting the Raf/Mek/Erk and/or VEGF pathways in combination with inhibiting the mTOR
pathway may be another useful strategy for the treatment of TSC-related tumors.
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Background
Tuberous sclerosis complex (TSC) is a fairly common
inherited tumor suppressor syndrome, characterized by
the development of hamartomas in the brain, skin, kid-
neys, lungs, heart and other organs [1,2]. There is signifi-
cant morbidity due to a variety of clinical issues that occur
at high frequency including epilepsy, cognitive and/or
behavioral impairments, kidney disease, pulmonary lym-
phangioleiomyomatosis (LAM), disfiguring facial angiofi-
bromas, and other manifestations [2-5].
TSC1 and TSC2, which code for hamartin and tuberin
respectively, have been identified as the disease genes of
TSC [6,7]. The two gene products form a tumor suppres-
sor complex that regulates a conserved cellular signaling
pathway (PI3K/Akt/mTOR) that mediates protein synthe-
sis and cell proliferation [8-11]. Tuberin's GTPase-activa-
tion of Rheb (the small GTPase Ras homologue enriched
in brain) is responsible for the tumor suppressor effect of
the tuberin-hamartin complex. Rheb in turn directly regu-
lates the mammalian target of rapamycin complex 1
(mTORC1) in the PI3K/Akt/mTOR pathway [7,12,13].
When the hamartin-tuberin complex is not functional,
elevated levels of active Rheb (Rheb-GTP) constitutively
activate mTOR, ultimately resulting in abnormal protein
translation. This in turn causes increased cell growth, pro-
liferation, and survival [9-11,14].
Rapamycin (Rapamune™ or sirolimus, Wyeth, Madison,
NJ), an FDA-approved mTOR inhibitor for immunosup-
pression following kidney transplantation, has been shown
to ameliorate disregulated mTOR signaling in cells that lack
normal hamartin or tuberin [15]. Furthermore, rapamycin
and some of its analogs have successfully treated TSC-
related tumors, seizures, and cognitive defects in relevant
rodent disease models [16-22]. Rapamycin treatment was
also effective in reducing TSC-related kidney angiomyol-
ipomas with tolerable side effects in human clinical trials
[23,24], and tumor regression was observed in a case series
of TSC patients with brain tumors (subependymal giant
cell tumors, also known as SGCTs or SEGAs) who were
treated with off-label rapamycin [25]. There are several
rapamycin analogs (CCI-779, RAD001, and AP23575) that
are also under investigation as anti-tumor agents [26,27].
One of these, CCI-779 (Torisel™ or temsirolimus, Wyeth,
Madison, NJ), has been FDA-approved for the treatment of
advanced renal cell carcinoma [28].
While rapamycin effectively reduces the size of many TSC-
associated tumors in humans, tumor regression does not
occur in all cases and tumor regrowth is generally
observed with the cessation of treatment [23-25].
Although the response results in early human trials are
encouraging, it is possible that a longer term use of
rapamycin may be more effective. Identification of other
active drugs is also of interest to improve the response rate
and/or durability of response. There is some evidence that
other drug classes, including inhibitors of VEGF signaling,
interferon gamma (IFN-g), HMG-CoA reductase inhibi-
tors, and MMP inhibitors may be useful in treating TSC
and/or LAM.
There is increasing evidence that VEGF signaling plays an
important role in the pathogenesis of TSC and LAM.
Brain, kidney and skin tumors associated with TSC are
known to be vascular [29], and TSC2 loss is associated
with elevated levels of HIF and VEGF in cultured cells
[30]. Furthermore, in recent biomarker studies of the
VEGF family, serum levels of VEGF-D were found to be
significantly elevated in patients with sporadic or TSC-
associated LAM as compared with healthy controls and
patients with other pulmonary illnesses [31,32]. The
importance of VEGF signaling in TSC and LAM suggests
that combination therapies that aim to inhibit mTOR sig-
naling along with disrupting VEGF signaling may be more
successful than single agents. Sorafenib (also known as
BAY 43-9006 and Nexavar™) is an oral multi-targeted
kinase inhibitor that inhibits VEGFR-1, VEGFR-2, and
VEGFR-3 in addition to the Raf/Mek/Erk pathway,
PDGFR, FLT-3, and c-KIT [33,34]. It is also FDA-approved
for the treatment of advanced renal cell carcinoma and
advanced hepatocellular carcinoma. As a result of its
inhibitory effects on angiogenic and tumorigenic molecu-
lar targets, sorafenib may be useful for treating TSC-
related tumors.
The cytokine interferon-gamma (IFN-g) is another candi-
date therapeutic agent for the treatment of TSC because
the presence of a high-expressing IFN-g allele has been
linked to significantly reduced kidney tumor burdens in
Tsc2+/- mice relative to the tumor burden in the kidneys of
Tsc2+/- mice with normal IFN-g levels [35]. Furthermore,
we found an association between the presence of a high-
expressing IFN-g allele and reduced frequency of kidney
angiomyolipomas in a cohort of human TSC patients
[36]. IFN-g has also shown to be effective as a single agent
in the treatment of TSC-related lesions in mouse models
when IFN-g treatment is initiated while tumors are small
and given for a long duration [18,19]. Recently, however,
we observed that a short term course of IFN-g treatment in
combination with CCI-779 did not significantly reduce
kidney disease in Tsc2+/- mice when treatment was used to
treat larger tumors [20]. As such, the clinical utility of
treating TSC-related tumors with the combination of IFN-
g plus an mTOR inhibitor is still unclear.
Statins and MMP inhibitors are drug classes of interest
because there is some evidence that they may be useful
therapeutic agents for TSC. In a recent study, atorvastatin
was found to inhibit the proliferation of Tsc2-/- mouse
embryo fibroblasts while also inhibiting constitutive
phosphorylation of mTOR, S6 kinase, and S6 in Tsc2-/-
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cells [37]. The antibiotic, doxycycline, is an MMP inhibi-
tor that has been shown in a case report to reduce MMP
levels in urine from a LAM patient. Furthermore, reduc-
tion in urine MMP levels in that case correlated with
improvement of pulmonary function [38]. There is also
some in vitro data suggesting that doxycycline inhibits
MMP activity and invasiveness of cells isolated from LAM
tissue [39].
We completed a series of preclinical studies in an effort to
address issues relevant to making decisions regarding the
next generation of clinical trials for TSC and/or LAM.
Since mutations in TSC2 are more common and more
severe compared to mutations in TSC1 [4], we used TSC2
mouse models for these studies. The Tsc2+/- mouse is
genetically similar to most humans with TSC, and they
develop age-related kidney tumors that mimic important
aspects of TSC-related kidney disease. We also used a Tsc2-
/- subcutaneous tumor model that reflects the loss of het-
erozygosity (LOH) observed in TSC-related kidney and
brain tumors [40,41] as a generic model for TSC-related
tumors. Specifically, we investigated the efficacy of
rapamycin and rapamycin plus IFN-g using a dosing
schedule that included a prolonged duration of weekly
maintenance therapy using the Tsc2+/- kidney tumor
model. We also evaluated the utility of a VEGF pathway
inhibitor (sorafenib), a HMG-CoA reductase inhibitor
(atorvastatin), and an MMP inhibitor (doxycycline) using
the subcutaneous Tsc2-/- tumor model. These studies on
new drug classes were done in the Tsc2-/- subcutaneous
tumor model because it is a relatively high throughput
preclinical model relevant to TSC and/or LAM. All drugs
were tested as single agents and in combination with
rapamycin.
Methods
Treatment of Tsc2+/- mice with IFN-g and rapamycin
The Tsc2+/- mouse is heterozygous for a deletion of exons
1–2 as previously described [42]. The Tsc2+/- cohort used
in this experiment was obtained by crossing these Tsc2+/-
Table 1: Summary of Tsc2+/- results from this study and Messina et al., 2007
Untreated Rapamycin Combination 
rapamycin plus IFN-g
Untreated CCI-779 
(6–8 months)
CCI-779 
(10–12 months)
Number of mice (n) 12 24 24 12 12 12
Tumor score per kidney 
(ave. ± Std. Err.)
15.00 ± 2.01 0.83 ± .018 0.77 ± 0.20 9.95 ± 1.59 6.00 ± 1.01 3.54 ± 0.76
Percent decrease in tumor 
score per kidney with 
treatment
- 94.5% 94.9% - 39.7% 64.4%
Age of kidney tumor 
analysis
13 months 13 months 13 months 12 months 12 months 12 months
P value (vs. untreated) - P < 0.0001 P < 0.0001 - - -
P value (vs. rapamycin) P < 0.0001 na P = 0.82 P < 0.0001* P < 0.0001* P < 0.0001*
Dose of daily rapamycin 
(5 days/week)
- 8 mg/kg per day 8 mg/kg per day - - -
Ages, daily rapamycin 
treatment
- 6–7 months and 12–
13 months
6–7 months and 12–
13 months
- - -
Dose of daily IFN-g 
(5 days/week)
- - 20,000 IU - - -
Ages, daily IFN-g 
treatment
- - 6–7 months and 12–
13 months
- - -
Dose of maintenance 
rapamycin 
(1 dose per week)
- 16 mg/kg per week 16 mg/kg per week - - -
Ages, weekly rapamycin 
treatment
- 7–12 months 7–12 months - - -
Dose of daily CCI-779 
(5 days/week)
- - - - 8 mg/kg per day 8 mg/kg per day
Ages, daily CCI-779 
treatment
- - - - 6–8 months 10–12 months
This study Messina et al., 
2007
* Tumor score from indicated group from Messina et al., 2007 compared with rapamycin group from this study
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mice with wild-type C57BL/6 mice. In order to avoid bias
due to strain variation, sibling littermates were used as
controls. Tsc2+/- mice were assigned to one of three
cohorts: rapamycin 8 mg/kg IP, rapamycin 8 mg/kg plus
IFN-g 20,000 units IP, and untreated. All mice receiving
drug therapy were treated in three consecutive parts: In
part one, mice were treated daily (5 days/week, Monday
through Friday) for one month (6 months ≤ age < 7
months) with their assigned treatments by intraperitoneal
injection (IP). In part two, all mice in both the rapamycin
and rapamycin plus IFN-g cohorts stopped their assigned
daily treatment and started a weekly 16 mg/kg mainte-
nance dose of rapamycin for five months (7 months ≤ age
< 12 months). In the final part, all mice restarted the same
treatment they received from 6–7 months of age for one
final month (see Table 1). The two month-long periods of
daily rapamycin treatment before and after the mainte-
nance treatment were included so that we can compare
the results of this study with our previous preclinical stud-
ies that also include a total of two months of daily treat-
ment without the weekly maintenance treatment phase.
All mice were euthanized at 13 months of age according
to institutional animal care guidelines. We evaluated kid-
ney disease at 13 months in this experiment instead of 12
months in prior studies [18,20] because kidney disease
severity is likely to be higher in older mice, and we rea-
soned that this may allow us to better detect small differ-
ences between treatment groups. The severity of kidney
disease was determined in all animals using quantitative
histopathology as described below.
We selected the timing of rapamycin and IFN-g doses and
schedules based on our prior findings showing treatment
at 6–8 months or 10–12 months to be most effective
using this model [20]. Rapamycin powder was obtained
from LC Laboratories (Woburn, MA) and a 20 mg/ml
stock of rapamycin was made in ethanol (stored at -20°C
for up to one week). The stock solution was diluted to 1.2
mg/ml in vehicle (0.25% PEG, 0.25% Tween-80) for the 8
mg/kg dose and diluted to 2.4 mg/ml in vehicle for the 16
mg/kg dose. Murine IFN-g (R&D Systems, Minneapolis,
MN) was diluted to 100,000 units/ml in sterile phosphate
buffered saline (PBS) containing 0.1% mouse serum albu-
min (Sigma-Aldrich, Inc., St. Louis, MO) and stored at
4°C. All treatments were administered within 24 hours of
making them. The health and behavior of all study ani-
mals were checked daily. Animals were weighed weekly,
and at the time of necropsy, there were no significant dif-
ferences in weight between cohorts. All experiments were
done according to animal protocols approved by our
institutional animal protocol review committee (Chil-
dren's Hospital Boston, Boston, MA) and were compliant
with federal, local, and institutional guidelines on the care
of experimental animals.
Quantification of kidney cystadenomas in Tsc2+/- mice
For histological quantification of kidney cystadenomas,
each kidney was fixed and sliced at 1 mm intervals. The
kidney sections were then arranged sequentially for paraf-
fin embedding, sectioning, and staining with hematoxylin
and eosin (H&E). All slides were coded to keep scoring
blinded, and all cystadenomas were counted, measured,
and scored according to the scale shown in Table 2 by two
blinded researchers (CW and AN). Cystadenomas that
extended into more than one 1 mm kidney slice were
counted only once and scored according to the maximum
diameter.
Since the kidney cystadenomas of these Tsc2+/- mice can be
divided into subgroups including cystic, pre-papillary,
papillary and solid lesions, we use "kidney cystadenomas"
to refer to the entire spectrum of kidney lesions observed.
In addition to analyzing data according to all cystadeno-
mas, a subgroup analysis was also done by coding cystic,
pre-papillary, papillary, and solid kidney lesions sepa-
rately as indicated in Table 3. This is a slight modification
to subgroup categories reported previously [20].
Induction of subcutaneous Tsc2-/- tumors in nude mice
Nude mice (strain CD-1nuBR, up to 6–8 weeks old) were
obtained from Charles River Laboratories, Inc. (Wilming-
ton, Massachusetts) and injected subcutaneously on the
dorsal flank with 2.5 million NTC/T2null (Tsc2-/-, Trp53-/-
Table 2: Scoring scale for kidney cystadenomas
Score Area Range (mm2)
1 0.01 < x ≤ 0.09
2 0.09 < x ≤ 0.2
3 0.2 < x ≤ 0.35
4 0.35 < x ≤ 0.5
5 x > 0.5
Areas of cystadenomas were calculated by multiplying
the longest axis and its perpendicular axis.
Table 3: Kidney Cystadenoma Subtypes
Lesion Subtype Percentage Filled
Cystic 0%
Pre-papillary 0%< x < 25%
Papillary 25% ≤ x < 100%
Solid 100%
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) cells. As soon as tumors became visible, they were meas-
ured Monday through Friday using calipers. Tumor vol-
umes were calculated using the formula: length × width ×
width × 0.5 [43]. All mice were euthanized once tumors
reached ~3000 mm3 in accordance with institutional ani-
mal care guidelines. Please note that survival analysis is
done using time to tumor volume of ~3000 mm3, because
this is when animals are euthanized. According to a pro-
tocol similar to our previous studies [18,20,21], data
points for graphs of average tumor volume growth repre-
sent days when at least four mice in the indicated treat-
ment group had tumor measurements. Statistical
comparison of tumor volume measurements between
groups is done on the last day that relevant groups had at
least four tumor measurements.
Treatment of subcutaneous tumors with sorafenib and 
rapamycin
Twenty-four CD-1 nude mice bearing Tsc2-/- tumors were
randomly assigned to one of four treatment arms: gavage
vehicle (untreated control), rapamycin 8 mg/kg IP, soraf-
enib 60 mg/kg by gavage, or rapamycin 8 mg/kg IP plus
sorafenib 60 mg/kg by gavage (see Table 4). Treatment
was started once the tumors reached a volume of ~150
mm3 (day 1 of treatment). Rapamycin treated mice
received 200 μl of a 1.2 mg/ml solution of rapamycin
daily (5 days per week, Monday through Friday) by IP
injection. According to drug level testing, average rapamy-
cin levels are ~12–40 ng/ml from 24–72 hours after a sin-
gle 8 mg/kg dose of rapamycin. As trough levels for
standard rapamycin dosing in humans is 3–20 ng/ml, the
dosing used in these studies is relevant to rapamycin dos-
ing in humans. Sorafenib treated mice received 60 mg/kg
of sorafenib daily Monday through Friday by oral gavage.
Sorafenib pills were obtained from the Brigham and
Women's Hospital research pharmacy, crushed and
diluted to make a 10 mg/ml suspension in 5% glucose for
oral gavage stock. The sorafenib dose was based on pre-
clinical studies in which daily oral administration of sor-
afenib at 30 to 60 mg/kg produced complete tumor stasis
during treatment in five of six tumor models tested
[34,44]. Rapamycin was prepared as previously described.
The control group (gavage vehicle) received 200 μl of a
5% glucose solution daily Monday through Friday by oral
gavage.
The health and behavior of all mice were checked daily,
and we did not observe significant toxicity from treatment
with rapamycin, sorafenib, or the combination of
rapamycin plus sorafenib at the doses used in this study.
Once tumors reached the endpoint volume of ~3000
mm3, the mice were sacrificed. Upon sacrifice, whole
blood and tumor tissue were harvested. Mice were
weighed on day one of their treatment and at necropsy; no
notable changes were seen in any cohorts (data not
shown).
Two mice were excluded from the analyses. One mouse
assigned to the rapamycin 8 mg/kg daily IP group was
euthanized due to weight loss and dehydration prior to
starting any drug treatments. Another mouse assigned to
rapamycin 8 mg/kg plus sorafenib 60 mg/kg daily treat-
ment was removed from study due to an extremely slow
growing tumor that did not reach treatment threshold vol-
umes. Both mice that were excluded did not start any
treatments prior to euthanasia so their conditions were
Table 4: Rapamycin plus sorafenib is more effective than single agent rapamycin in subcutaneous Tsc2-/- tumors
Untreated Rapamycin Sorafenib Combination Rapamycin plus Sorafenib
Number of mice (n) 6 5 6 5
Median survival (days) 24.5 46 19.5 53
P value (survival) - 0.0014* NS* 0.0014* 0.0018#
Day 16, average tumor volume (mm3) 1454 ± 215 284 ± 52 2209 ± 499 293 ± 68
P value (day 16) - 0.0007* NS* 0.0009*
Day 43, average tumor volume (mm3) - 2499 ± 222 - 1665 ± 245
P value (day 43) - - - 0.036#
Day 44, average tumor volume (mm3) - 2607 ± 247 - 1820 ± 245
P value (day 44) - - - 0.06#
Rapamycin (5 days per week) - 8 mg/kg per day - 8 mg/kg per day
Sorafenib (5 days per week) - - 60 mg/kg per day 60 mg/kg per day
*compared to untreated
#compared to rapamycin treated
NS, not significant
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unrelated to study treatments. All drug doses were calcu-
lated based on an average weight of 30 g per mouse.
Treatment of subcutaneous tumors with atorvastatin, 
doxycycline, and rapamycin
To determine if atorvastatin or doxycycline are useful ther-
apeutic drugs for TSC, the efficacy of atorvastatin and dox-
ycycline as single agents and in combination with
rapamycin were tested in the subcutaneous tumor model
for TSC-related tumors. A cohort of 48 CD-1 nude mice
was injected with NTC/T2null (Tsc2-/-, Trp53-/-) cells. The
cohort was then divided into 6 randomly assigned groups:
untreated control group, single agent rapamycin, atorvas-
tatin, combination atorvastatin plus rapamycin, single
agent doxycycline, and combination doxycycline plus
rapamycin (see Table 5).
All drug treatments started when tumors reached a vol-
ume of ~50 mm3 (day 1 of treatment), regardless of treat-
ment schedule, and animals were euthanized when
tumors reached a volume of ~3000 mm3. If a volume of
40 mm3 was reached on Thursday or Friday, treatment
began that day. Otherwise, treatment was started on the
day tumor volume was ≥50 mm3. Untreated mice did not
receive any treatment even after tumors reach a volume
≥50 mm3. Please note that this is a minor difference in
study design from the sorafenib study. We have previously
shown that differences in tumor volume at the start of
treatment are not likely to have any major impact on effi-
cacy [20].
Rapamycin treated groups received 200 μl of a 1.2 mg/ml
solution of rapamycin (8 mg/kg) three times per week (on
Mondays, Wednesdays and Fridays) by IP injection. Mice
being treated with doxycycline were treated daily Monday
through Friday with 200 μl of a 1.5 mg/ml (10 mg/kg) IP
injection. Atorvastatin groups received 200 μl daily of a 3
mg/ml solution (20 mg/kg) by IP injection Monday
through Friday. All drug doses were calculated based on
an average weight of 30 g per mouse. Atorvastatin powder
was obtained from LKT Laboratories, Inc. (St. Paul, MN)
and was diluted in 1% ethanol in sterile PBS. This dose of
atorvastatin was based on a study [45] in which this dose
was effective in reducing atherosclerotic lesions in a
mouse model. Doxycycline powder was obtained from
Sigma-Aldrich Co. (St. Louis, MO) and was diluted in ster-
ile PBS. This 10 mg/kg dose of doxycycline was based on
a study of the efficacy of minocycline and doxycycline in
treating Huntington's Disease, which showed the dose to
be biologically active but not effective in treating Hunt-
ington's Disease [46]. Rapamycin preparation was
described above.
Once tumors reached the endpoint volume of ~3000
mm3, the mice were sacrificed. Animal behavior and
health were monitored daily, and animals were weighed
Table 5: Summary of atorvastatin and doxycycline preclinical data
Untreated Rapamycin Atorvastatin Combination 
Rapamycin plus 
Atorvastatin
Doxycycline Combination 
Rapamycin plus 
Doxycycline
Number of mice (n) 8 8 8 8 8 8
Median survival 
(days)
28 41.5 32.5 55.5 28 43
P value (survival) - 0.003* NS* 0.0006* NS# NS* 0.007* NS#
Day 26, average 
tumor volume (mm3)
1865 ± 532 544 ± 110 1931 ± 298 390 ± 186 1749 ± 352 1117 ± 421
P value (day 26) - 0.011* NS* 0.04* NS* NS*
Day 42, average 
tumor volume (mm3)
- 1784 ± 643 - 1188 ± 338 - 2419 ± 570
P value (day 42) - - - NS# - NS#
Rapamycin 
(IP, 3 days per week)
- 8 mg/kg, 3 days per 
week
- 8 mg/kg, 3 days per 
week
- 8 mg/kg, 3 days per 
week
Atorvastatin 
(IP, 5 days per week)
- - 20 mg/kg per day 20 mg/kg per day - -
Doxycycline 
(IP, 5 days per week)
- - - - 10 mg/kg per day 10 mg/kg per day
*compared to untreated
#compared to rapamycin treated
NS, not significant
BMC Pharmacology 2009, 9:8 http://www.biomedcentral.com/1471-2210/9/8
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at the start of the study and at the time of necropsy. While
there were no significant differences in weight at necropsy
between cohorts, all mice receiving rapamycin failed to
gain weight as other cohorts do (Table 6). We did not
observe other evidence of toxicity from treatment with
rapamycin, atorvastatin, doxycycline, or combinations at
the doses used in this study. All mice from rapamycin
treated cohorts were euthanized 24 hours after the last
rapamycin treatment upon reaching the endpoint tumor
volume. Upon sacrifice, whole blood and tumor were har-
vested for drug level testing.
Whole blood and tumor rapamycin levels
Whole blood or tumor rapamycin levels were measured
from a subset of animals treated with rapamycin in the
nude mouse treatment studies described above. Blood
and tumors were harvested at necropsy 24 hours after the
final treatment of rapamycin. Tumor samples were pre-
pared by homogenizing 200 mg of tumor tissue in 1 ml of
sterile PBS. Whole blood was obtained through cardiac
puncture, dispensed into an EDTA-containing blood col-
lection tube, and diluted with an equal volume of sterile
phosphate buffered saline to ensure sufficient volume for
rapamycin level analysis. All measured rapamycin levels
were then corrected according to sample dilution at time
of analysis. Tumor samples and whole blood samples
were tested for rapamycin levels at the Clinical Laboratory
at Children's Hospital Boston (Boston, Massachusetts).
The range of detection is 0.5 to 100 ng/ml of rapamycin.
Statistical analyses
GraphPad Prism software (version 4.01) was used for all
data analysis, with p-value ≥ 0.05 indicating statistical sig-
nificance. All calculations were completed from raw data
by three authors (NL, AN, and CW) and verified with cal-
culations from two other authors (AR and MM). A stand-
ard unpaired t test was used to test all quantitative data,
and the Mantel-Cox logrank analysis was used for survival
data, which is defined as time to reach a tumor volume of
~3000 mm3.
Results
Comparison of rapamycin with combination rapamycin 
plus IFN-g in Tsc2+/- mice treated using a schedule that 
includes daily dosing and weekly maintenance therapy
In prior studies, combination therapy was more effective
than single agent CCI-779 in the treatment of nude mice
bearing Tsc2-/- tumors, but we saw no difference between
these groups in the Tsc2+/- kidney tumor model. In order
to further evaluate the potential benefits of mTOR inhibi-
tor plus IFN-g combination therapy in the Tsc2+/- kidney
tumor model, we compared single agent rapamycin treat-
ment to rapamycin plus IFN-g treatment using a dosing
schedule that includes daily treatment (five days per
week) for one month before and after a period of weekly
maintenance treatment for five months.
Relative to the untreated cohort, both treatment groups
showed a significantly lower disease burden as evaluated
by kidney cystadenoma score (Figure 1a). No significant
difference was observed in kidney cystadenoma score
between the rapamycin treated cohort and the combina-
tion treated cohort. This result is similar to the finding we
reported in Messina et al. 2007 in a Tsc2+/- mouse study,
but differs from our observation using the subcutaneous
Tsc2-/- tumor model [19]. In this case, we note that the sin-
gle agent rapamycin treatment group was extremely effec-
tive and reduced kidney disease by 94.5% compared with
untreated controls.
We also analyzed this data according to kidney lesion sub-
type (Figure 1b). All Tsc2+/- kidney lesions can be subdi-
vided into four categories: cystic lesions, pre-papillary
lesions, papillary lesions, and solid lesions. Cystadeno-
Table 6: Rapamycin treated nude mice with Tsc2-/- tumors fail to gain weight
Weight at Start (g) Weight at Necropsy (g) Weight gain (g) P value
Untreated 34.6 ± 1.1 37.8 ± 0.9 3.2 ± 0.9 *0.0388
-
-
Rapamycin treated 36.0 ± 0.6 35.6 ± 0.6 -0.4 ± 0.6 *NS
**NS
#NS
Other treatment 33.8 ± 0.6 36.8 ± 0.7 3.1 ± 0.4 *0.0024
**NS
#NS
*Weight at start compared with weight at necropsy (within the same treatment group)
**Weight at start compared to untreated at start
#Weight at necropsy compared to untreated at necropsy
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mas were scored according to lesion subtype (see Table 3)
to investigate the impact of treatment on lesion subtype as
well as document the distribution of these subtypes in
untreated animals. Papillary lesions were the most com-
mon subtype in untreated Tsc2+/- mice while cystic and
solid lesions were the least common. Cystic lesions were
most common in the rapamycin treated cohort, and solid
lesions appeared most often in the rapamycin and IFN-g
combination treated cohort. Treatment with rapamycin
alone or combination rapamycin plus IFN-g reduced the
score of all subtypes of kidney lesions.
Combination of rapamycin plus sorafenib (a VEGF 
pathway inhibitor) is more effective than single agent 
rapamycin
In order to evaluate whether inhibition of VEGF signaling
is a useful therapeutic strategy for the treatment of TSC-
related tumors, we investigated the efficacy of sorafenib as
a single agent and in combination with rapamycin in
treating a relevant subcutaneous tumor model (see meth-
ods). We used nude mice bearing subcutaneous Tsc2-/-
tumors derived from NTC/T2null (Tsc2-/-, Trp53-/-) cells
with the following cohorts: untreated controls, rapamycin
treated, sorafenib treated, and sorafenib plus rapamycin
combination treated.
Average tumor growth is shown for each treatment group in
Figure 2a and Table 4. According to our protocol, the data
points shown represent days when at least four mice of the
treatment group were treated and had tumors measured
(see Methods). We compared tumor volumes of single
agent treatment to untreated controls on day 16 because
that was the last day that all three groups (untreated,
rapamycin, sorafenib) had at least four tumor measure-
ments. Consistent with our prior studies, the rapamycin
treated group had a significantly lower tumor volume than
the untreated group (284 ± 52 mm3 for rapamycin, 1454 ±
215 mm3 for untreated, p = 0.0007). Single agent sorafenib
was not effective as the day 16 tumor volume was 2209 ±
499 mm3, which is not significantly different from the
untreated control group. Survival analysis comparing single
agent treatment to untreated controls was in agreement
with the tumor volume comparisons.
We also compared combination sorafenib plus rapamycin
with single agent rapamycin treatment to evaluate the
potential utility of VEGF pathway plus mTOR pathway
inhibition. Comparing survival curves (see Figure 2b and
Table 4) using the Mantel Cox logrank analysis, we
observed improved survival in the combination sorafenib
plus rapamycin treatment group (median survival of 53
days) compared with the rapamycin treatment group
(median survival of 46 days, p = 0.0018). We also com-
pared tumor volumes in these two groups. According to
our protocol, we compared tumor volumes on treatment
day 44 (that was the last day that both groups had at least
Comparison of single agent rapamycin treatment to rapamycin plus IFN-g treatment in Tsc2+/- mice using a dosing schedule that includes weekly maintena ce rapamycin treatmentFig r  1
Comparison of single agent rapamycin treatment to rapamycin plus IFN-g treatment in Tsc2+/- mice using a 
dosing schedule that includes weekly maintenance rapamycin treatment. Severity of kidney disease in Tsc2+/- mice 
was quantified by scoring (a) total kidney cystadenomas and (b) kidney lesion subtype for indicated treatment groups (see 
treatment details in methods and Table 1). Lesion subtypes include cystic, pre-papillary, papillary, and solid; for a definition of 
each subtype and scoring details, see Tables 2 and 3. The red error bars in (a) indicate a statistically significant difference (p < 
0.05) relative to the untreated cohort. Statistical analysis was not done for the lesion subtype date. These data show a signifi-
cant reduction of kidney disease in both treatment groups but no difference between single agent rapamycin and combination 
rapamycin plus IFN-g. Error bars shown indicate standard error.
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four tumor measurements) and found the average tumor
volume of the rapamycin plus sorafenib treated group
(1820 ± 245 mm3, n = 5) was smaller than the average
tumor volume of the rapamycin treated group (2607 ±
247 mm3, n = 4); this difference approaches statistical sig-
nificance (p = 0.06). In this case, we also compared tumor
volumes on day 43 when there were tumor measurements
for all mice in both groups, the difference was statistically
significant (1665 ± 245 mm3 for rapamycin plus soraf-
enib; 2499 ± 222 mm3 for single agent rapamycin, p =
0.036).
Atorvastatin as a single agent or in combination with 
rapamycin does not decrease tumor burden or increase 
survival in nude mice bearing Tsc2-/- tumors
As shown in Figure 3 and Table Table 5, atorvastatin did
not reduce tumor growth or improve survival as a single
agent. Furthermore, adding atorvastatin to rapamycin did
not reduce disease severity when compared with single
agent rapamycin treatment. Data points for average tumor
volume (Figure 3a) are included on days where at least four
of the animals in a cohort had tumors measured. The day
26 average tumor volume (mean ± standard error) was 544
± 110 mm3 for the rapamycin group and 390 ± 186 mm3
for atorvastatin plus rapamycin. These were significantly
lower than the day 26 average tumor volume for the
untreated cohort (1865 ± 532 mm3). In contrast, the day 26
average tumor volume for single agent atorvastatin (1931 ±
298 mm3) was not significantly different than the untreated
group. The day 26 average tumor volume for single agent
atorvastatin was significantly higher than the rapamycin
cohort, while the average tumor volume for atorvastatin
plus rapamycin did not differ significantly from the average
tumor volume for the single agent rapamycin cohort.
At day 42, the average tumor volume for atorvastatin plus
rapamycin group (1188 ± 338 mm3) was not significantly
lower than the single agent rapamycin cohort (1784 ± 643
mm3). Survival data from this experiment is shown in Fig-
ure 3b and Table 5. We observed a significant improve-
ment in median survival for both the rapamycin group
(41.5 days, p = 0.003) and the atorvastatin plus rapamy-
Improved survival and decreased tumor growth in nude mice bearing Tsc2-/- tumors with combination rapamycin plus sorafenib treatmentFigure 2
Improved survival and decreased tumor growth in nude mice bearing Tsc2-/- tumors with combination rapamy-
cin plus sorafenib treatment. (a) Average tumor volume over time. Error bars shown indicate standard error. (b) Survival 
curve for indicated treatment cohorts. Based on survival analysis, rapamycin plus sorafenib is more effective than single agent 
rapamycin. Based on tumor volume analyses, the rapamycin plus sorafenib treated group is not statistically different from the 
rapamycin treated group on day 44. However, on the last day that tumor volume data was available for all mice (day 43), there 
was a significant difference between tumor volumes from the rapamycin plus sorafenib group compared with the single agent 
rapamycin group. Although rapamycin is an effective single agent, sorafenib is not. This data is summarized in Table 4.
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cin group (55.5 days, p = 0.0006) when compared to the
untreated cohort (28 days). However, the median survival
between the rapamycin treated group and the atorvastatin
plus rapamycin treated group was not significantly differ-
ent. Although the median survival of atorvastatin treated
animals (32.5 days) was slightly longer than in the
untreated cohort, this difference was also not statistically
significant. In summary, the survival data together with
the tumor volume data demonstrate that we did not
observe any benefit to adding atorvastatin to rapamycin
treatment in this preclinical TSC tumor model.
Doxycycline as a single agent or in combination with 
rapamycin does not decrease tumor burden or increase 
survival in nude mice bearing Tsc2-/- tumors
Tumor volume and survival data for the doxycycline
treated mice along with rapamycin treated and untreated
control group are shown in Figure 4 and Table 5. Figure 4a
shows average tumor growth over time for the doxycycline
treated animals. The data points represent days where at
least four of the animals in a cohort had tumors meas-
ured. The day 26 average tumor volumes (mean ± stand-
ard error) for the single agent doxycycline cohort (1749 ±
352 mm3) and the doxycycline plus rapamycin treated
animals (1117 ± 421 mm3) were not significantly differ-
ent than the untreated group (1865 ± 532 mm3). The aver-
age tumor volume for doxycycline plus rapamycin (2419
± 570 mm3) was similar to the rapamycin cohort (1784 ±
643 mm3) at day 42 (Figure 4a, Table 5), and survival data
for the doxycycline experiment was consistent with the
tumor volume data (Figure 4b). The median survival of
the doxycycline plus rapamycin treated cohort (43 days, p
= 0.007) was significantly increased compared to the
untreated cohort (28 days) but was similar to rapamycin
treated animals. The median survival of the doxycycline
cohort (28 days) was not significantly different than the
untreated cohort. In summary, doxycycline was not effec-
tive as either a single agent or in combination with
rapamycin in this preclinical model for TSC-related
tumors.
Sorafenib, atorvastatin and doxycycline do not affect 
rapamycin levels in combination treatment cohorts
Rapamycin is metabolized by CYP3A4 so rapamycin lev-
els can vary when there is exposure to other drugs that
either induce or inhibit CYP3A4 [47]. To be sure there
Atorvastatin does not decrease tumor growth or increase survival in nude mice bearing Tsc2-/- tumorsFigure 3
Atorvastatin does not decrease tumor growth or increase survival in nude mice bearing Tsc2-/- tumors. (a) Aver-
age tumor growth over time for atorvastatin and atorvastatin plus rapamycin treated animals. Error bars shown indicate stand-
ard error. (b) Survival over time for atorvastatin and atorvastatin plus rapamycin cohorts. Based on survival analysis and 
comparison of tumor volumes on days 26 and 42, atorvastatin was not effective as a single agent or in combination with 
rapamycin in this preclinical study. This data is summarized in Table 5.
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were no significant drug interaction issues in our studies,
rapamycin levels were measured in tumors or whole
blood 24 hours after the last dose in a subset of animals
from our studies (Figure 5). Average tumor rapamycin lev-
els (mean ± standard deviation) in the sorafenib plus
rapamycin treated group (167.8 ± 63.1 ng/ml) and the
rapamycin treated group (257.6 ± 91.6 ng/ml) were not
statistically different (p = 0.14, NS). Average blood
rapamycin levels (mean ± standard deviation) from nei-
ther the atorvastatin plus rapamycin group (42.2 ± 19.3
ng/ml, p = 0.96, NS) nor the doxycycline plus rapamycin
group (38.9 ± 10.8 ng/ml, p = 0.68, NS) were statistically
different from the average blood rapamycin level of the
single agent rapamycin group (42.9 ± 24.7 ng/ml). We
have previously observed higher 24 hour rapamycin levels
in tumor tissue when compared with blood [21] so the
differences in tumor versus blood levels shown in Figure
5 are consistent with our prior results. Based on drug level
testing, we conclude that sorafenib, atorvastatin, and dox-
ycycline did not significantly affect the metabolism of
rapamycin in the preclinical studies reported here.
Discussion
In prior preclinical studies, we used two TSC2 tumor
models to demonstrate that while both the rapamycin
analog, CCI-779, and IFN-g are effective in reducing
tumor growth, rapamycin is more effective than CCI-779,
and effective rapamycin doses are absorbed after topical
administration [18-21]. We also investigated the optimal
timing of treatment [20] using these models. We observed
conflicting results regarding whether treatment with an
mTOR inhibitor plus IFN-g is better than an mTOR inhib-
itor as a single agent [19,20].
The preclinical studies reported here were done to address
questions relevant to the design of future TSC clinical tri-
als. One goal of the Tsc2+/- experiment was to compare the
combination of rapamycin plus IFN-g to single agent
rapamycin using a dosing schedule for rapamycin that
included daily treatment and weekly treatment. Although
we did not see any benefit to the addition of IFN-g, we
also noted that the rapamycin single agent treatment was
very effective. We observed a dramatic 94.5% reduction in
tumor burden in Tsc2+/- mice treated with one month of
daily rapamycin treatment before and after five months of
weekly rapamycin therapy. Although IFN-g clearly has
Doxycycline does not decrease tumor growth or increase survival in nude mice bearing Tsc2-/- tumorsFigure 4
Doxycycline does not decrease tumor growth or increase survival in nude mice bearing Tsc2-/- tumors. (a) Aver-
age tumor growth over time for doxycycline and doxycycline plus rapamycin treated animals. Error bars shown indicate stand-
ard error. (b) Survival over time for doxycycline and doxycycline plus rapamycin cohorts. Based on survival analysis and 
comparison of tumor volumes on days 26 and 42, doxycycline was not effective as a single agent or in combination with 
rapamycin in this preclinical study. This data is summarized in Table 5.
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activity in some of our prior studies [18,19], we observed
that IFN-g seems to be effective when given for a pro-
longed period of time and is not as effective when given
only short term (this study and Messina et al. 2007). In
this study, the single agent rapamycin treatment was so
effective that it would be difficult to improve on the
94.5% reduction in kidney disease severity that was
observed.
This dramatic result in the rapamycin single agent group
prompted us to review our prior studies. As illustrated in
Table 7, we see a 94.5% reduction in kidney disease in
Tsc2+/- mice treated with daily rapamycin for one month
before and after weekly rapamycin for five months in this
study. In contrast, two months of daily CCI-779 without
maintenance therapy was effective but only reduced dis-
ease severity by 64.5% [20]. A comparison of the Tsc2+/-
preclinical results from Messina et al., 2007 to this study
is summarized in Table 1. Treatment with rapamycin
(daily for one month followed by weekly for five months
and then daily for the last month, this study) showed sig-
nificantly lower tumor burden than both the 6–8 months
and 10–12 months CCI-779 treated cohorts from Messina
et al. (p < 0.0001; p < 0.0001) [20].
In Messina et al. (2007), we showed that the severity of
kidney disease increases with an increase in age in
untreated Tsc2+/- mice [20]. It is interesting to point out
that the CCI-779 treated cohorts were evaluated for sever-
ity of kidney disease at 12 months of age (Messina et al.
2007), and rapamycin treated cohorts were evaluated at
13 months of age (this study). According to our previous
data on the genesis of kidney disease at different ages, the
mice euthanized at 13 months of age should have a higher
severity of kidney disease than those euthanized at 12
months of age. Untreated Tsc2+/- mice euthanized at 12
months were found to have an average score per kidney of
9.95 ± 1.59 while untreated Tsc2+/- mice euthanized at 13
months were found to have an average score per kidney of
15.00 ± 2.01. The observation that the older rapamycin
treated cohort (0.83 ± 0.18 average score per kidney)
showing less tumor burden than the younger CCI-779
treated cohorts (treated 6–8 months, average score per
kidney 6.00 ± 1.01; treated 10–12 months, average score
per kidney 3.54 ± 0.76) is even more striking when this
study design difference is considered.
While prior studies also examined mTOR inhibitor efficacy
in treating TSC-related kidney lesions, several inter-study dif-
ferences are limitations that prevent rigorous comparisons.
One difference between this study and Messina et al. (2007)
is that different mTOR inhibitors were used. Although
rapamycin and CCI-779 are similar, we have recently shown
that rapamycin (8 mg/kg IP 5 days per week) is more effec-
tive than CCI-779 (8 mg/kg IP 5 days per week) in the Tsc2-/
- subcutaneous tumor model, raising the possibility that the
difference is due to rapamycin's higher efficacy as compared
to CCI-779 rather than the addition of prolonged weekly
maintenance dosing. Interestingly, when we compare data
from two prior CCI-779 studies [18,20], we noted that CCI-
779 given at a lower dose 3 times per week for 3 months is
more effective than CCI-779 given daily for 2 months (84%
reduction in Lee et al. 2005 versus 64% reduction in Messina
et al. 2007, see Table 7). This is somewhat surprising as the
total CCI-779 dose per mouse used in Lee et al. 2005 (4.32
mg) is lower than in Messina et al. 2007 (9.6 mg). Possible
Sorafenib, atorvastatin and doxycycline do not affect whole blood rapamycin levels in nude mice bearing Tsc2-/- tumorsFigure 5
Sorafenib, atorvastatin and doxycycline do not affect whole blood rapamycin levels in nude mice bearing Tsc2-/
- tumors. (a) Tumor rapamycin levels from rapamycin treated group (n = 5) and sorafenib plus rapamycin combination treated 
group (n = 4). (b) Whole blood rapamycin levels from rapamycin treated group (n = 8), atorvastatin plus rapamycin combina-
tion treated group (n = 8) and doxycycline plus rapamycin combination treated group (n = 8). Rapamycin levels were measured 
24 hours after the last dose of rapamycin for all groups.
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minor strain variation between the Tsc2+/- mice used in the
different studies is another potential difference that limits
rigorous direct comparisons. Despite the study differences,
taken together, our observations suggest that lower doses of
an mTOR inhibitor for a longer duration may be more effec-
tive in TSC preclinical models. This will be further investi-
gated and may have implications for future TSC clinical
trials.
In early clinical studies, rapamycin treatment causes TSC-
related tumor regression [23,24]. Because this tumor
regression is incomplete and responses are not durable
[24], there is significant interest in identifying novel
agents for TSC-related tumors to be used either as single
agents or in combination with rapamycin. In this study,
we evaluated three novel drug classes: a multi-targeted
kinase inhibitor (sorafenib), a statin (atorvastatin), and
an MMP inhibitor (doxycycline) as single agents and in
combination with rapamycin. We found that combina-
tion sorafenib plus rapamycin was more effective than
rapamycin according to survival analysis, but the differ-
ence was not dramatic and we were surprised by the lack
of benefit of single agent sorafenib. Limitations of this
study include the small numbers in each treatment group
and that only a single dose of sorafenib was tested. It is
possible that single agent sorafenib may be effective at
higher doses or earlier treatment. Because of the potential
for an effect due to drug interactions, we measured
rapamycin levels and found that there was no significant
difference in rapamycin levels in the presence or absence
of sorafenib treatment. In our sorafenib plus rapamycin
experiment, although the improvements were not dra-
matic, it was statistically significant for survival analysis
and approached statistical significance for tumor volume
analysis on day 44. While the improvements in tumor size
were not statistically significant on day 44, it is important
to note that these improvements were statistically signifi-
cant when comparing the groups on day 43 when both
cohorts had all five assigned mice. By day 44, a rapamycin
treated mouse had reached a tumor volume of ~3000
mm3 and had been sacrificed so that it was not included
in the day 44 tumor volume analysis. Because our proto-
col incorporates this bias against finding a difference
between rapamycin treated and combination treated
groups by excluding measurements of tumor volumes
beyond ~3000 mm3 (when mice must be euthanized), the
data presented here suggest that further study into VEGF
inhibitors in combination with rapamycin is warranted.
Furthermore, this data is consistent with other published
data showing that VEGF signaling is important in TSC dis-
ease pathogenesis. Based on these positive findings, we
are enthusiastic about further investigating VEGF signal-
ing in TSC & LAM pathogenesis and additional TSC pre-
clinical studies evaluating other VEGF pathway inhibitors
as well as different schedules and dosing of the combina-
tion of VEGF inhibitors plus rapamycin.
In contrast, doxycycline (an MMP inhibitor) and atorvas-
tatin (a HMG-CoA reductase inhibitor) were not effective
as single agents or in combination with rapamycin. A lim-
itation of this study is that only one dose was tested, so it
is possible that a higher dose or different schedule could
alter these results. Another limitation is that tumor cells
for subcutaneous injection into nude mice were p53 null
in addition to Tsc2-/-. We submitted blood samples for
rapamycin level testing to be sure that there was no evi-
dence of significant drug interaction issues. Although our
findings are not consistent with in vitro studies showing
that atorvastatin inhibits the proliferation of Tsc2-/- cells
[37] and doxycycline decreases invasiveness of cells
derived from LAM tissue [39], these studies were done
using cultured cells, which is an important difference.
Table 7: Comparison of Tsc2+/- mTOR inhibitor trials
mTOR inhibitor Total drug dose (per mouse) Schedule % Reduction in kidney 
tumors
Study
Rapamycin 19.2 mg Part one: 8 mg/kg daily × 1 
month
94.5%* This study
Part two: 16 mg/kg weekly × 5 
months
Part three: 8 mg/kg daily × 1 
month
CCI-779 9.6 mg 8 mg/kg daily × 2 months 63%* Messina et al. 2007
64%**
CCI-779 4.32 mg 4 mg/kg 3 times a week × 3 
months
83.6%** Lee et al. 2005
* Kidney tumor score
**Kidney tumor number
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Based on our findings, we are not enthusiastic about pur-
suing further preclinical studies or clinical trials with these
drug classes.
Conclusion
The results of the preclinical studies reported here indicate
that prolonged exposure to relatively low doses of mTOR
inhibitors may be a useful strategy to achieve more dura-
ble responses of TSC-related tumors and should be pur-
sued in further preclinical studies and TSC trials.
Furthermore, survival data in a TSC preclinical model sug-
gests that the combination of rapamycin plus sorafenib, a
multi-targeted kinase inhibitor that targets the VEGF path-
way, may be more effective than single agent rapamycin.
This finding has implications for evaluation of other ang-
iogenesis and multi-targeted kinase inhibitors in future
TSC preclinical studies and demonstrates that targeting
multiple signaling pathways may be a useful strategy for
the treatment of TSC.
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